TORONTO, March 09, 2018 (GLOBE NEWSWIRE) — Canada House Wellness Group Inc. (CSE:CHV) (“Canada House” or the “Company”) is pleased to announce that it has been selected to be featured by the Innovations TV Series in the second quarter of this year on Fox Business.

Innovations with Ed Begley Jr. is particularly interested in how Canada House is treating complex health issues through ongoing education, support, and data-driven cannabinoid treatment therapy.

Operating in concert, the three Canada House subsidiaries generate world-leading data and drive shareholder value through the delivery of cannabinoid therapy services (Marijuana For Trauma Inc.), evidence-based treatment plans (Knalysis Technology) and high quality medical cannabis (Abba Medix).

In this episode, Innovations will explore how Canada House improves Canadians’ lives through client-focused, evidence-based cannabis patient solutions and products. Focusing on three distinct sectors, the show will educate viewers on how Canada House and its subsidiaries treat complex health issues through ongoing education and data-driven cannabinoid therapy treatment, leverage data generated by its own operations to improve patient outcomes, and produce efficacious cannabis genetics and products to help its patient base achieve optimum health outcomes.

“We grew tired of anecdotal information, especially where your health is concerned. Why are doctors determining a course of treatment by saying, ‘We heard this strain can help with {this or that illness},’” said Paul Methot, President of Knalysis Technologies, a division of Canada House. “This is why we built our software platforms.  We are actually quantifying the efficacy of medical cannabis.  We believe that we are the only technology company doing this, using our proprietary methodology, and are thrilled at the opportunity of sharing our work with the Innovations audience.”

“Canada House and its subsidiaries generate world-leading data and shareholder value through the delivery of cannabinoid therapy services,” said Michele Nehls, Senior Producer for the Innovations series. “We hope to help others by bringing this information to the masses.”

About Canada House Wellness Group Inc.:
Canada House is the parent company of Marijuana for Trauma Inc., Knalysis Technologies and Abba Medix Corp. The Company’s goal is to become a marketplace leader through strategic partnerships, mergers, and acquisitions to create a fully integrated cannabis therapy company. For more information please visit or

For further information, please contact:
Boom Capital Markets
Steve Low

Canada House Wellness Group, Inc.
Larry Bortles

About Innovations and DMG Productions:
Innovations, hosted by award winning actor Ed Begley, Jr., is an information-based series geared toward educating the public on the latest breakthroughs in all areas of society. Featuring practical solutions and important issues facing consumers and professionals alike, Innovations focuses on cutting-edge advancements in everything from health and wellness to global business, renewable energy, and more.

Backed by experts in various fields, and a team dedicated to education and advancement, DMG Productions consistently produces commercial-free, educational programming on which both viewers and networks depend.

For more information visit or call (866) 496-4065.

Cautionary Statement Regarding ForwardLooking Information. Certain statements within this news release pertaining to the Company constitute “forwardlooking statements”, within the meaning of applicable securities laws, including without limitation, statements regarding future estimates, business plans and/or objectives, sales programs, forecasts and projections, assumptions, expectations, and/or beliefs of future performance, are “forwardlooking statements”. Such “forwardlooking statements” involve known and unknown risks and uncertainties that could cause actual and future events to differ materially from those anticipated in such statements. Forwardlooking statements include, but are not limited to, statements with respect to the anticipated effects of the financing, regulatory changes, timeliness of government approvals for the granting of permits and licenses, changes in medical marijuana prices, actual operating performance of facilities, competition and other risks affecting the Company in particular and the medical marijuana industry generally, including those set out in the Company’s public disclosure record. The Company assumes no responsibility to update or revise forwardlooking information to reflect new events or circumstances unless required by law.

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.